CEOs of GlaxoSmithKline tapping their R&D investments in Korea

The chief executive officers of GlaxoSmithKline in U.K. have made their frequent visits to Korea to tap the possibility of promoting business collaboration with the Korean counterpart in the domestic bioindustry arena.

Chairman Robert A. Ingram was the first visitor to Korea last March, followed by International General Manager Howard Pien at the end of last April, and Finance CEO John Coom...